Treatment of chronic atrial fibrillation with warfarin or aspirin: A cost-effectiveness and cost-utility analysis.

被引：0
|
作者：
Zarnke, KB [1 ]
Levine, MAH [1 ]
OBrien, B [1 ]
机构：
[1] ST JOSEPHS HOSP, CTR EVALUAT MED, HAMILTON, ON, CANADA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 1996年 / 59卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
下载
收藏
页码：PII89 / PII89
页数：1
相关论文
共 50 条
  • [41] How Big Is the Impact of the Warfarin Cost on the Cost-Effectiveness of Rivaroxoban for Stroke Prevention in Atrial Fibrillation?
    Sanaei, Omid
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (09): : 1384 - 1385
  • [42] Cost-Effectiveness of Oral Anticoagulants for Treatment of Atrial Fibrillation
    Canestaro, William J.
    Patrick, Amanda R.
    Avorn, Jerry
    Ito, Kouta
    Matlin, Olga S.
    Brennan, Troyen A.
    Shrank, William H.
    Choudhry, Niteesh K.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2013, 6 (06): : 724 - +
  • [43] COST-EFFECTIVENESS OF DRONEDARONE FOR THE TREATMENT OF ATRIAL FIBRILLATION IN CHINA
    Tian, L.
    Wang, L.
    Jianhao, J.
    Zhang, M. R.
    Ren, Y.
    VALUE IN HEALTH, 2021, 24 : S72 - S72
  • [44] Cost-effectiveness in medical and interventional treatment in atrial fibrillation
    Cohen, A.
    Leclercq, C.
    ARCHIVES OF CARDIOVASCULAR DISEASES SUPPLEMENTS, 2016, 8 (02) : 144 - 156
  • [45] THE USE OF THE PROPENSITY SCORE IN THE COST-EFFECTIVENESS ANALYSIS OF THE ATRIAL FIBRILLATION TREATMENT
    Kamensky, V
    Bulkova, V
    Bohacova, J.
    VALUE IN HEALTH, 2017, 20 (09) : A615 - A616
  • [46] The Adoption of Cost-Effectiveness Acceptability Curves in Cost-Utility Analyses
    Meckley, Lisa M.
    Greenberg, Dan
    Cohen, Joshua T.
    Neumann, Peter J.
    MEDICAL DECISION MAKING, 2010, 30 (03) : 314 - 319
  • [47] Modelled cost-effectiveness and cost-utility analysis of various treatment strategies in osteoporotic postmenopausal women in Poland
    Orlewska, E
    Lis, J
    VALUE IN HEALTH, 2002, 5 (06) : 477 - 477
  • [48] The cost-effectiveness of warfarin (Coumadin®) vs. ximelagatran (Exanta®) for the treatment of atrial fibrillation.
    Ellis, SL
    Ulrich, HC
    Arant, TW
    Sullivan, PW
    PHARMACOTHERAPY, 2005, 25 (03): : 471 - 471
  • [49] THE COST-EFFECTIVENESS OF PEGASPARGASE FOR FIRST-LINE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA: A COST-UTILITY ANALYSIS
    Basu, S.
    Lin, P. L.
    Saha, V
    VALUE IN HEALTH, 2017, 20 (09) : A444 - A444
  • [50] The Cost-Effectiveness of Pegaspargase for First-Line Treatment of Acute Lymphoblastic Leukaemia: A Cost-Utility Analysis
    Basu, S.
    Lin, P.
    Rowntree, C.
    Saha, V.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S112 - S113
12345